Limits...
Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.

Rygiel AM, Milano F, Ten Kate FJ, Bergman JJ, Krishnadath KK - J Oncol (2010)

Bottom Line: Further, we confirmed Her-2 amplification on corresponding biopsies that were taken at the same occasion as the cytologybrushings.Then, we compared the FISH results with IHC data obtained from the corresponding biopsies and showed that low level of Her-2 amplification does not correlate with Her-2 protein overexpression (score +3/+2; P = 1), in contrast to the high amplification level (P = .001).Thus, in our population of BE and EAC patients, low level of Her-2 amplification does not result in detectable level of Her-2 protein as assessed by IHC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

ABSTRACT
An accurate evaluation of the Her-2 status has important prognostic and therapeutic implications in many carcinomas. The aim of the study was to correlate Her-2 locus (17q11.2) amplification and chromosome 17 gains as assessed by fluorescent in situ hybridization (FISH) with Her-2 protein overexpression by immunohistochemistry (IHC) in patients with Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). We analyzed 34 patients with Her-2 amplification and/or chromosome 17gains using FISH on brush cytology specimens. Seven patients (21%) showed high Her-2 locus amplification (Her-2: Cep17 >/= 5 : 1), 5 (15%) showed low Her-2 locus amplification (Her-2: Cep17 >/= 2 < 5 : 1), and 22 (65%) displayed gains of chromosome 17 only. Further, we confirmed Her-2 amplification on corresponding biopsies that were taken at the same occasion as the cytologybrushings. Then, we compared the FISH results with IHC data obtained from the corresponding biopsies and showed that low level of Her-2 amplification does not correlate with Her-2 protein overexpression (score +3/+2; P = 1), in contrast to the high amplification level (P = .001). Thus, in our population of BE and EAC patients, low level of Her-2 amplification does not result in detectable level of Her-2 protein as assessed by IHC.

No MeSH data available.


Related in: MedlinePlus

Her-2 protein and Her-2 locus status as determined by IHC on BE biopsy and FISH on BE brush cytology specimens. (a) Strong overexpression of Her-2 protein (+3) in HGD, (b) moderate overexpression of Her-2 protein (+2) in EAC, (c) no overexpression of Her-2 protein (score 0) in EAC, (d) no overexpression of Her-2 protein (score 0) in LGD, (e) no overexpression of Her-2 protein (score 0) in ND, (f) high level of Her-2 locus amplification (clusters) in a cytology sample of a HGD case—CEP 17 (green) and Her-2 locus (red), (g) gain of chromosome 17 in a cytology sample of an EAC case—CEP 17 (green) and Her-2 locus (red), (h) low level of Her-2 amplification (ratio  ≥2 < 5  :  1 of Her-2: Cep17) in a cytology sample of an EAC case, CEP 17 (green) and Her-2 locus (red), (i) gain of chromosome 17 in a cytology sample of a LGD case—CEP 17 (green) and Her-2 locus (red), and (j) two copies of chromosome 17 (disomy) and Her-2 locus (normal pattern) in a cytology sample of a ND case—CEP 17 (green) and Her-2 locus (red).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2902046&req=5

fig1: Her-2 protein and Her-2 locus status as determined by IHC on BE biopsy and FISH on BE brush cytology specimens. (a) Strong overexpression of Her-2 protein (+3) in HGD, (b) moderate overexpression of Her-2 protein (+2) in EAC, (c) no overexpression of Her-2 protein (score 0) in EAC, (d) no overexpression of Her-2 protein (score 0) in LGD, (e) no overexpression of Her-2 protein (score 0) in ND, (f) high level of Her-2 locus amplification (clusters) in a cytology sample of a HGD case—CEP 17 (green) and Her-2 locus (red), (g) gain of chromosome 17 in a cytology sample of an EAC case—CEP 17 (green) and Her-2 locus (red), (h) low level of Her-2 amplification (ratio ≥2 < 5  :  1 of Her-2: Cep17) in a cytology sample of an EAC case, CEP 17 (green) and Her-2 locus (red), (i) gain of chromosome 17 in a cytology sample of a LGD case—CEP 17 (green) and Her-2 locus (red), and (j) two copies of chromosome 17 (disomy) and Her-2 locus (normal pattern) in a cytology sample of a ND case—CEP 17 (green) and Her-2 locus (red).


Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.

Rygiel AM, Milano F, Ten Kate FJ, Bergman JJ, Krishnadath KK - J Oncol (2010)

Her-2 protein and Her-2 locus status as determined by IHC on BE biopsy and FISH on BE brush cytology specimens. (a) Strong overexpression of Her-2 protein (+3) in HGD, (b) moderate overexpression of Her-2 protein (+2) in EAC, (c) no overexpression of Her-2 protein (score 0) in EAC, (d) no overexpression of Her-2 protein (score 0) in LGD, (e) no overexpression of Her-2 protein (score 0) in ND, (f) high level of Her-2 locus amplification (clusters) in a cytology sample of a HGD case—CEP 17 (green) and Her-2 locus (red), (g) gain of chromosome 17 in a cytology sample of an EAC case—CEP 17 (green) and Her-2 locus (red), (h) low level of Her-2 amplification (ratio  ≥2 < 5  :  1 of Her-2: Cep17) in a cytology sample of an EAC case, CEP 17 (green) and Her-2 locus (red), (i) gain of chromosome 17 in a cytology sample of a LGD case—CEP 17 (green) and Her-2 locus (red), and (j) two copies of chromosome 17 (disomy) and Her-2 locus (normal pattern) in a cytology sample of a ND case—CEP 17 (green) and Her-2 locus (red).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2902046&req=5

fig1: Her-2 protein and Her-2 locus status as determined by IHC on BE biopsy and FISH on BE brush cytology specimens. (a) Strong overexpression of Her-2 protein (+3) in HGD, (b) moderate overexpression of Her-2 protein (+2) in EAC, (c) no overexpression of Her-2 protein (score 0) in EAC, (d) no overexpression of Her-2 protein (score 0) in LGD, (e) no overexpression of Her-2 protein (score 0) in ND, (f) high level of Her-2 locus amplification (clusters) in a cytology sample of a HGD case—CEP 17 (green) and Her-2 locus (red), (g) gain of chromosome 17 in a cytology sample of an EAC case—CEP 17 (green) and Her-2 locus (red), (h) low level of Her-2 amplification (ratio ≥2 < 5  :  1 of Her-2: Cep17) in a cytology sample of an EAC case, CEP 17 (green) and Her-2 locus (red), (i) gain of chromosome 17 in a cytology sample of a LGD case—CEP 17 (green) and Her-2 locus (red), and (j) two copies of chromosome 17 (disomy) and Her-2 locus (normal pattern) in a cytology sample of a ND case—CEP 17 (green) and Her-2 locus (red).
Bottom Line: Further, we confirmed Her-2 amplification on corresponding biopsies that were taken at the same occasion as the cytologybrushings.Then, we compared the FISH results with IHC data obtained from the corresponding biopsies and showed that low level of Her-2 amplification does not correlate with Her-2 protein overexpression (score +3/+2; P = 1), in contrast to the high amplification level (P = .001).Thus, in our population of BE and EAC patients, low level of Her-2 amplification does not result in detectable level of Her-2 protein as assessed by IHC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

ABSTRACT
An accurate evaluation of the Her-2 status has important prognostic and therapeutic implications in many carcinomas. The aim of the study was to correlate Her-2 locus (17q11.2) amplification and chromosome 17 gains as assessed by fluorescent in situ hybridization (FISH) with Her-2 protein overexpression by immunohistochemistry (IHC) in patients with Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). We analyzed 34 patients with Her-2 amplification and/or chromosome 17gains using FISH on brush cytology specimens. Seven patients (21%) showed high Her-2 locus amplification (Her-2: Cep17 >/= 5 : 1), 5 (15%) showed low Her-2 locus amplification (Her-2: Cep17 >/= 2 < 5 : 1), and 22 (65%) displayed gains of chromosome 17 only. Further, we confirmed Her-2 amplification on corresponding biopsies that were taken at the same occasion as the cytologybrushings. Then, we compared the FISH results with IHC data obtained from the corresponding biopsies and showed that low level of Her-2 amplification does not correlate with Her-2 protein overexpression (score +3/+2; P = 1), in contrast to the high amplification level (P = .001). Thus, in our population of BE and EAC patients, low level of Her-2 amplification does not result in detectable level of Her-2 protein as assessed by IHC.

No MeSH data available.


Related in: MedlinePlus